Approval · Notice of Compliance 28955 · 2022
RAPAMUNE: Notice of Compliance 28955
Issued September 13, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28955
- Date
- September 13, 2022
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Updates to the Product Monograph (PM) with drug-drug interactions with letermovir and cannabidiol and PM conversion to the 2020 master template.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RAPAMUNE | Not yet assigned | — |